In June 2010, OraQuick® HCV Rapid Antibody Test became the first rapid HCV point-of-care test to be approved by the FDA. In February 2011, OraQuick became the first rapid HCV test to be FDA-approved for fingerstick whole blood specimens. As of April 2012, OraQuick HCV Rapid Antibody Test is the only HCV point-of-care test that is FDA-approved and CLIA-waived.
Since the launch of OraQuick in June 2010, OraSure has been a leader in distributing thousands of tests in the United States, helping people learn their HCV antibody status in as little as 20 minutes, helping to link HCV+ patients to care.
OraSure Technologies is a leader in the development, manufacture and distribution of rapid point-of-care infectious disease tests, collection devices and other technologies designed to detect or diagnose critical medical conditions. Its innovative products include rapid tests for the detection of antibodies to HIV and HCV at the point of care and testing solutions for detecting various drugs of abuse. In addition, through its wholly-owned subsidiary, DNA Genotek Inc., the Company also is a leading provider of oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications.
OraSure’s portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians’ offices, and commercial and industrial entities. The Company’s products enable healthcare providers to deliver critical information to patients, empowering them to make decisions to improve and protect their health. For more information on OraSure Technologies, please visit www.orasure.com.